This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
07/28/15 - 3:58:20 PM ET (BATS BZX Real-time Price)
Div Yield: --
ARQL Day's Range
ARQL 52 Week Range
ARQL Business Summary
ArQule, Inc., a clinical-stage biotechnology company, researches and develops therapeutics for the treatment of cancer and rare diseases.View ARQL key stats
Arqule Inc - ARQL - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Arqule Inc as a
Sell with a ratings score of D-.
Report Snippet: We rate ARQULE INC (ARQL) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.